Surmodics (SRDX) Aandeel Koers
Surmodics Koers
In de afgelopen 19 jaar liet Surmodics de omzet jaarlijks met 3,8% groeien tot 126,08 Miljoen USD. De winst per aandeel is de afgelopen 15 jaar met 8,2% per jaar gedaald. Bij Surmodics is de nettowinstmarge met -9,2% ten opzichte van 1,2% enkele jaren geleden gedaald. Het consensus-koersdoel voor Surmodics op 12 maanden bedraagt 43,86 USD, circa 2,0% boven de huidige koers. Van de 9 analisten geven 6 het aandeel een koopadvies — per saldo een Kopen-consensus.
Surmodics aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Surmodics bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Surmodics
Surmodics Inc. is a medical technology company that operates through two segments: Medical Devices and In Vitro Diagnostics. The company's business model revolves around developing and commercializing innovative products and technologies that enhance the diagnosis and treatment of diseases. Surmodics' Medical Devices segment focuses on providing surface modification technologies to medical device manufacturers, enabling them to improve device performance and biocompatibility. On the other hand, the In Vitro Diagnostics segment offers proprietary diagnostic technologies and reagent coatings for various healthcare tests. Through its diversified business model, Surmodics strives to contribute to the advancement of medical care and improve patient outcomes.
Surmodics Inc is primarily active in the healthcare and medical device industry.
The main competitors of Surmodics Inc in the market include Medtronic, Abbott Laboratories, and Boston Scientific Corporation.
Surmodics Inc, founded in 1979, is a leading provider of surface modification and in vitro diagnostic technologies. With its headquarters in Eden Prairie, Minnesota, the company develops and manufactures innovative products that enhance the performance of medical devices, improve drug delivery, and support the diagnosis of various diseases. Surmodics has a rich history of pioneering advancements in healthcare, and its expertise in surface modification has helped it establish collaborations with renowned medical device manufacturers globally. As a trusted name in the industry, Surmodics Inc continues to drive innovation and deliver solutions that positively impact patient outcomes and empower healthcare professionals worldwide.
Surmodics Inc has achieved significant milestones in its history. The company introduced its first medical device coating product, SurfaSeal, in 1985, which marked a breakthrough in the field. In 1998, Surmodics launched its first drug delivery coating called BioFX. The company developed StabilCoat Plus, a surface modification technology used in cardiovascular devices in 2003. In 2019, Surmodics received FDA approval for its SurVeil™ drug-coated balloon, offering a breakthrough treatment option for peripheral artery disease patients. With continuous innovation and dedication, Surmodics Inc strives to make impactful advancements in the medical technology industry.
Surmodics Inc is primarily present in the United States.
Surmodics Inc is a leading provider of medical device and in vitro diagnostic technologies. The company operates with a strong set of values and corporate philosophy that underpins its actions and decisions. Surmodics is committed to innovation, continuously striving to develop breakthrough solutions that positively impact patient outcomes. The company places a strong emphasis on integrity, conducting business with the highest ethical standards and fostering a culture of accountability. Surmodics also embraces collaboration, working closely with customers, partners, and internal teams to deliver the most advanced solutions. With a focus on quality, Surmodics ensures that its products meet the highest standards of reliability and performance, putting patient safety and well-being at the forefront of its operations. Overall, Surmodics Inc represents a commitment to innovation, integrity, collaboration, and quality in the medical device industry.
Analisten hanteren momenteel een gemiddeld koersdoel van 43,86 USD voor het aandeel Surmodics (mediaan: 43,86 USD), oftewel +2,0 % ten opzichte van de laatste koers. De consensus is gebaseerd op 9 analistenratings.
7 analisten beoordelen het aandeel Surmodics momenteel: 0 adviseren kopen, 4 houden en 3 verkopen. Voor 2026 verwachten analisten dat Surmodics een omzet van 123,01 Miljoen USD en winst per aandeel van -0,12 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Surmodics op 38,36 EUR (42,98 USD).
Het aandeel Surmodics (SRDX) is genoteerd aan 2 beurzen, waaronder: NASDAQ (SRDX), Frankfurt (SU6.F).
Surmodics Inc. is a renowned manufacturer of medical devices and products used in in vitro diagnostics, medical technology, and drug delivery. The company offers a wide range of innovative solutions based on nanotechnology and surface chemistry. Its core competencies include the development and manufacturing of medical coatings that can be applied to polymers, metals, and glass. These coatings are capable of improving the performance and extending the lifespan of medical devices and products. Surmodics Inc. also specializes in the development and manufacturing of reagents and detection devices for in vitro diagnostics, offering specialized kits and assays for quick and reliable determination of clinical parameters such as blood sugar levels or inflammation indicators. In the field of medical technology, Surmodics Inc. is mainly focused on the development of minimally invasive catheters and implants. These products are equipped with special coatings that prevent the penetration of bacteria and other pathogens, thus minimizing the risk of infections. Surmodics Inc. is also a key player in the drug delivery market, offering a wide range of products based on micro and nanotechnology. These include implants that release precisely dosed active ingredients, as well as intelligent delivery systems that automatically adapt to the individual needs of the patient. Surmodics Inc. is a strong and highly innovative company known for its continuous product development and quality assurance. The company works closely with its customers to develop individual solutions that meet their specific requirements.
De verwachte omzet van Surmodics bedraagt 123,01 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Surmodics bedraagt -1,72 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Surmodics bedraagt momenteel -356,44. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Surmodics-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Surmodics bedraagt momenteel 4,97. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Surmodics-aandeel.
De Eulerpool Kwaliteitsscore voor Surmodics is 2/10.
De ISIN van Surmodics is US8688731004. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Surmodics is 914178. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Surmodics is SRDX. Onder dit beurstickersymbool wordt het Surmodics-aandeel op de beurs verhandeld.
Surmodics aandeel
Surmodics Peer Group
Surmodics Ticker
Surmodics FIGI
Alle fundamentals en diepgaande analyse van Surmodics
Onze aandelenanalyse van het Surmodics-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Surmodics. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: